Exposure-response analysis to assess the concentration-QTc relationship of CC-122.
CC-122 hydrochloride is a novel pleiotropic pathway modifier compound that binds cereblon, a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex. CC-122 has multiple activities including modulation of immune cells, antiproliferative activity of multiple myeloma and lymphoma cells, and antiangiogenic activity. CC-122 is being developed as an oncology treatment for hematologic malignancies and advanced solid tumors. Cardiovascular and vital sign assessments of CC-122 have been conducted in hERG assays in vitro and in a 28-day good laboratory practice monkey study with negative signals. To assess the potential concentration-QTc relationship in humans and to ascertain or exclude a small QT effect by CC-122, a plasma concentration exposure- and ΔQTcF-response model of CC-122 was developed. Intensive CC-122 concentration and paired triplicate electrocardiogram data from a single ascending dose study were included in the analysis. The parameters included in the final linear exposure-response model are intercept, slope, and treatment effect. The slope estimate of 0.0201 with 90% CI of (0.009, 0.035) indicates a weak relationship between ΔQTcF and CC-122 concentration. The upper bounds of the 90% CI of the model-predicted ΔΔQTcF effect at C max from the 4 mg clinical dose and the supratherapeutic dose of 15 mg (1.18 ms and 8.76 ms, respectively) are <10 ms threshold, suggesting that the risk of CC-122 QT prolongation effect at the relevant therapeutic dose range from 1 mg to 4 mg is low.
Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Yan
Y
Li
Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Leonidas N
LN
Carayannopoulos
Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Michael
M
Thomas
Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Maria
M
Palmisano
Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Simon
S
Zhou
QT prolongation effect; cardiovascular assessment
Blood. 2015 Aug 6;126(6):779-89
26002965
Ann Noninvasive Electrocardiol. 2014 Jan;19(1):70-81
24372708
J Pharmacol Toxicol Methods. 2016 Jul-Aug;80:1-8
26903171
Cancer Chemother Pharmacol. 2016 Feb;77(2):251-8
26754679
Clin Pharmacol Ther. 2015 Apr;97(4):326-35
25670536
Cancer Chemother Pharmacol. 2013 Nov;72 (5):1133-41
23999693
Prog Cardiovasc Dis. 2001 Mar-Apr;43(5 Suppl 1):1-45
11269621
Basic Clin Pharmacol Toxicol. 2013 Sep;113(3):179-86
23639045
Eur J Clin Pharmacol. 2016 May;72 (5):533-43
26879827
J Clin Pharmacol. 2008 Jan;48(1):13-8
18094216